Lung Cancer

Stephen Liu, MD, addresses the use of available therapies and the methods of overcoming acquired resistance in patients with ALK-positive non–small cell lung cancer.

John A. Kosteva, MD, clinical assistant professor of medicine, University of Pennsylvania School of Medicine, Abramson Cancer Center, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer (NSCLC).

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the application of liquid biopsies in non–small-cell lung cancer (NSCLC).

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies.

Marina Chiara Garassino, MD, reflects on the first-line approval of osimertinib, recent data with durvalumab, and the promise for combination chemoimmunotherapy in patients with non–small cell lung cancer.

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses ALK-targeted agents in the field of non–small cell lung cancer (NSCLC).

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

The FDA has granted a priority review designation to a supplemental biologics license application for first-line pembrolizumab for use in combination with carboplatin/paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer, regardless of PD-L1 expression.

David R. Gandara, MD, has pioneered groundbreaking therapies in lung cancer treatment through his leadership of interdisciplinary teams of oncologists, pharmacologists, molecular biologists, and statisticians.

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses PD-L1 expression in lung cancer.

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses the updated efficacy and safety data from the global phase III ALEX study of alectinib (Alecensa) versus crizotinib (Xalkori) in untreated advanced ALK-positive non–small cell lung cancer (NSCLC).

Lyudmila A. Bazhenova, MD, discusses treatments for patients with ALK-positive NSCLC, as well as the progress in less common oncogenic drivers, such as NTRK fusions.

Kathryn A. Gold, MD, discusses the evolving management of EGFR-mutant non–small cell lung cancer and the latest developments in small cell lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the combination of pegilodecakin (AM0010) and a PD-1 inhibitor in patients with advanced non–small cell lung cancer.